Physician profile
Jonathan A Feistmann
NPI 1447331087
$45,616.95
in general payments reported to CMS, 2019-2025
16 companies · $9,027 in 2025
The $9,027 reported for 2025 was more than what 95% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.01 · 2020: $60.45 · 2021: $287 · 2022: $3,661 · 2023: $11K · 2024: $21K · 2025: $9,027.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $31K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,250 · Food and Beverage: $2,761 · Travel and Lodging: $2,306 · Honoraria: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $30,723.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,250.00 |
| Food and Beverage | $2,761.16 |
| Travel and Lodging | $2,305.60 |
| Honoraria | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $32,979.84 | 2023-2025 | Clarus, Cirrus Hd-Oct, Forum |
| Carl Zeiss Meditec USA, INC. | $4,852.67 | 2022-2024 | Cirrus Hd-Oct, Veracity Surgical, Visumax |
| Alcon Vision LLC | $2,367.98 | 2025 | Unity, Clareon Panoptix Pro, Clareon |
| Apellis Pharmaceuticals, INC. | $1,816.48 | 2022-2024 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $1,571.14 | 2019-2025 | Eylea Hd, Eylea |
| Onmark, INC. | $1,440.13 | 2025 | |
| Mallinckrodt Hospital Products INC. | $251.27 | 2024-2025 | Acthar |
| Astellas Pharma US INC | $95.10 | 2023-2025 | Izervay |
| Genentech USA, INC. | $72.10 | 2023-2025 | Vabysmo, Lucentis |
| Eyepoint US, INC. | $44.84 | 2020-2021 | |
| Optos, INC. | $34.26 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $34.00 | 2022 | |
| Bausch & Lomb Americas INC. | $19.80 | 2024 | Stellaris |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| US Oncology Corporate, INC. | $17.94 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Feistmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.